Navigation Links
David Hooper Joins Evolution Marketing Research as Senior Director, Research
Date:4/29/2013

BLUE BELL, Pa., April 29, 2013 /PRNewswire/-- Evolution Marketing Research, a leading supplier of insights and intelligence to the healthcare industry, announces that David Hooper has joined the firm as Senior Director, Research. David leverages more than 13 years of experience leading and managing strategic research and analysis initiatives in the healthcare and pharmaceutical industries to further strengthen Evolution's specialized client services.

(Logo: http://photos.prnewswire.com/prnh/20130429/PH02684LOGO )

Most recently, David served as Director, Global Market Information & Research, at Warner Chilcott, LLC, a global specialty pharmaceutical company. In that role, David designed and led market research initiatives in support of in-line products and business development opportunities, and evaluated and modified data sources and internal reports to strengthen market insights. He implemented a new functional area consisting of market research, market analytics, and forecasting; developed a process and statistical model for brand/market level forecasting; and created tools to more effectively support the company's sales team.

"David not only brings to Evolution highly specialized experience in the pharmaceutical and healthcare industries, but also a clear commitment to improving processes related to research and analysis," said James E. Heasley II , Ph.D., Evolution Principal. "We look forward to sharing his expertise with our clients and continuing to strengthen our marketing research capabilities."

Prior to Warner Chilcott, David spent six years in market research at Merck & Co. and Schering-Plough Corporation. He also has several additional years of experience in other research and analytic roles, including previous global market research consulting experience. He received his B.A. in Psychology from Boston University, and his M.S., in Physiology and Biophysics, from Georgetown University.

About Evolution Marketing Research 
Evolution Marketing Research is a healthcare marketing research firm that provides qualitative and quantitative research, consulting services, project management, advisory board monitoring and other marketing research services to pharmaceutical, biotech and medical device companies all over the world. Company principals John Taenzler , Ph.D., Jim Cummings and James Heasley , Ph.D., who are backed by a seasoned team of analysts and researchers, bring their collective experience to bear on projects at all phases of the product lifecycle, from opportunity and licensing assessments, to product crafting in support of phase III clinical trial design, to development of the commercial platform for developmental and in-line products. To learn more, visit www.evolved-mr.com.

Contact: Karen Murray
215-850-4645

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE Evolution Marketing Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Can Science Really Get You Laid? The Shocking Truth About Dr. David Tan's "Desire System"
2. Dr. David Slaughter Launches Groundbreaking Cavity Prevention Program That Can Lower Decay Rates by 74%
3. Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort
4. David Smith Named Vice President of Operations for HealthTell
5. DuPont Congratulates David Hula for Highest Overall Yield with Pioneer® hybrid – P2088YHR in 2012 NCGA Corn Yield Contest
6. David Lichtenstein: Biotechnology is Rich Area for Investment
7. Renowned Operations and Supply Chain Expert Dr. David Simchi-Levi Joins OPS Rules
8. Maine Center for Creativity Selects Glenn Close and David Shaw to Receive Inaugural Maine Creative Industry Award
9. China Biologic Products Names Chairman David Gao to Additional Post of CEO
10. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
11. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, ... essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's ... is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
Breaking Biology News(10 mins):